ObsEva SA Stock News

Futures Steady After Fed-Inspired Rout As Tech, Bitcoin Slide Continues US equity futures were little changed after earlier swings as traders digested hawkish Fed minutes that sparked a global stock rout on Wednesday. As discussed yesterday, minutes from the Feds December meeting showed a growing preference for a faster path of rate hikes and a shrinking of the banks balance sheet (one which would lead to yet another market crash and even more stimulus). However, while rising rates is terrible news for tech and high duration names, it''s good news for the value sector, and investors bet while the Fed''s faster-than-expected policy tightening (which will lead to faster than expected easing) may crimp highly valued technology stocks it will offer opportunities in other equity sectors, and sure enough with Nasdaq futures bombing again, energy names like Exxon are at 2 year highs. Treasury yields extended a spike, with the 10Y rising to 1.75%, the dollar was unchanged and bitcoin''s plunge continued even though the selling in stocks has subsided.

ObsEva (OBSV) perks up 6.3% premarket after announcing positive topline results from Phase 3 EDELWEISS 3 trial of linzagolix, an oral GnRH antagonist, in women with

-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months-

GENEVA, Switzerland January 3 , 202 2 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today

Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.

GENEVA, Switzerland December 20, 2021 - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women''s reproductive health, today…

GENEVA, Switzerland December 20 , 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021.

ObsEva SA (NASDAQ:OBSV) was the target of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 3,240,000 shares, a growth of 40.9% from the November 15th total of 2,300,000 shares. Approximately 5.4% of the companys stock are short sold. Based on an average daily []

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval for ObsEva SA''s (NASDAQ: OBSV ) linzagolix, an oral GnRH antagonist to manage moderate to severe symptoms of uterine fibroids. If approved, linzagolix would be the first and only approved GnRH receptor antagonist with a non-hormonal Full story available on Benzinga.com

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval for ObsEva SA's (NASDAQ: OBSV) linzagolix, an oral

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland - December 13, 2021 - ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and comm

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

ObsEva SA (NASDAQ:OBSV) was the recipient of some unusual options trading activity on Wednesday. Investors bought 4,950 call options on the company. This represents an increase of approximately 861% compared to the average daily volume of 515 call options. Institutional investors have recently made changes to their positions in the business. Meitav Dash Investments Ltd. [] The post ObsEva Sees Unusually High Options Volume (NASDAQ:OBSV) appeared first on ETF Daily News .

-Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- -52-Week Data from the Phase 3 PRIMROSE